Clinical and epidemiologic burden of chronic myelogenous leukemia
Authors:
- Alberto RedaelliARAlberto Redaelli
- Christopher BellCBChristopher Bell
- Jodie CasagrandeJCJodie Casagrande
- Jennifer StephensJSJennifer Stephens
- Marc BottemanMBMarc Botteman
- Benjamin LaskinBLBenjamin Laskin
- Chris PashosCPChris Pashos
- 1 February 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 4 (1) , 85-96
Abstract
Chronic myelogenous leukemia represents 7-20% of all leukemia cases, with a worldwide incidence projected at less than one to two per 100,000 people. Approximately 85% of patients are diagnosed with chronic-phase chronic myelogenous leukemia and up to 40% are asymptomatic. Treatment strategies include chemotherapy, interferon-alpha therapy, transplantation (bone marrow/stem cell transplant) and imatinib mesylate (Gleevec), with the impact of treatment best realized during the chronic phase of the disease. Only transplantation has been clinically demonstrated to eradicate the Philadelphia chromosome, alter the natural course of the disease and cure patients diagnosed with chronic myelogenous leukemia. Interferon-alpha is currently considered for first-line treatment, however, the recent introduction of targeted therapy may change clinical practice. Ongoing research focused on new drug combinations and target therapies may eventually expand the armamentarium available to cure this disease.Keywords
This publication has 10 references indexed in Scilit:
- Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and ToxicitiesThe Oncologist, 2001
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 1997
- 9 Allografting for chronic myeloid leukaemiaBailliere's Clinical Haematology, 1997
- Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]Blood, 1995
- Quality of life following bone marrow transplantation: findings from a multicentre studyBritish Journal of Cancer, 1995
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study GroupBlood, 1993